NEW YORK, March 12, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding
H&R Block Inc. (NYSE: HRB), Ulta
Salon, Cosmetics & Fragrance, Inc. (NASDAQ: ULTA),
Myriad Genetics, Inc. (NASDAQ: MYGN), QIAGEN NV (NASDAQ: QGEN), and
Nutrisystem Inc. (NASDAQ: NTRI). Private wealth members receive
these notes ahead of publication. To reserve complementary
membership, limited openings are available at:
http://www.AnalystsReview.com/register
--
H&R Block Inc. Analyst Notes
On March 5, 2014, H&R Block
Inc. (H&R Block) announced that its Board of Directors has
declared a quarterly cash dividend of $0.20 per share. According to the Company,
shareholders of record as of March 17,
2014 can collect payments on April 1,
2014, which would also mark H&R Block's 206th
consecutive quarterly dividend since it went public in 1962. The
full analyst notes on H&R Block Inc. are available to download
free of charge at:
http://www.AnalystsReview.com/03122014/HRB/report.pdf
--
Ulta
Salon, Cosmetics & Fragrance, Inc. Analyst Notes
On March 3, 2014, Ulta Salon, Cosmetics & Fragrance, Inc.
(Ulta Beauty) reported that it has scheduled a conference call to
discuss its upcoming Q4 2013 and full-year 2013 financial results
on Thursday, March 13, 2014 at
5:00 p.m. ET/4:00 p.m. CT. The Company informed that
Mary Dillon, CEO, and Scott Settersten, CFO of the Company will host
the call. Ulta Beauty stated that a press release with details of
its Q4 2013 and full-year 2013 results will also be issued on the
aforesaid date after the market closes and prior to the call. The
full analyst notes on Ulta Salon,
Cosmetics & Fragrance, Inc. are available to download free of
charge at:
http://www.AnalystsReview.com/03122014/ULTA/report.pdf
--
Myriad Genetics, Inc. Analyst
Notes
On March 3, 2014, Myriad Genetics,
Inc. (Myriad) announced that data from its PROCEDE 500 study - a
prospective registry study that was designed to evaluate the impact
of the Prolaris test on physician treatment recommendations for
patients with prostate cancer, was published in the journal
Current Medical Research and Opinion. According to Myriad,
the data showed that 65% of physicians changed their original
treatment plans for men with prostate cancer based on results from
the Prolaris test. Prolaris is a 46-gene molecular diagnostic test
that has been evaluated in 11 clinical studies with more than 5,000
patients. "Prolaris is an absolute game changer for urologists
because it adds meaningful new prognostic information in terms of
risk assessment for prostate cancer patients that will improve
their care," said E. David Crawford,
M.D., Head of the Section of Urologic Oncology at the University of Colorado. "In this study, Prolaris
led to major changes in therapies with significant reductions or
increases in interventional treatments that were based on patients'
unique risk profiles." The full analyst notes on Myriad Genetics,
Inc. are available to download free of charge at:
http://www.AnalystsReview.com/03122014/MYGN/report.pdf
--
QIAGEN NV Analyst Notes
On February 26, 2014, QIAGEN NV
(QIAGEN) announced the commercial launch of
careHPV[TM] Test in
India. According to QIAGEN, the
careHPV[TM] Test is the
only molecular diagnostic for high-risk human papillomavirus (HPV)
designed to screen women in settings with limited healthcare
infrastructure, such as areas lacking electricity, water or
laboratories. "The launch of careHPV in India will help in efforts to reduce the high
burden of cervical cancer for women in India," said Dr. Victor Shi, President of QIAGEN Asia Pacific.
"With the digene HC2 HPV Test serving areas that have modern
healthcare infrastructure and the careHPV Test serving low-resource
areas, QIAGEN is expanding our role as the global leader in
preventive screening for cervical cancer and continuing to
contribute to women's health around the world." The full analyst
notes on QIAGEN NV are available to download free of charge at:
http://www.AnalystsReview.com/03122014/QGEN/report.pdf
--
Nutrisystem Inc. Analyst Notes
On February 26, 2014, Nutrisystem
Inc. (Nutrisystem) announced its Q4 2013 and full-year 2013
financial results. The Company posted revenues of $69.9 million in Q4 2013, up 11.8% YoY, while
full-year 2013 revenues dropped 9.8% YoY to $358.1 million. Q4 2013 GAAP net income was
$1.3 million as compared to a net
loss of $5.0 million in Q4 2012.
Full-year 2013 net income was $7.3
million or $0.25 per diluted
share, against a net loss of $2.8
million or loss per diluted share of $0.10. Commenting on the results, Nutrisystem's
CFO, Mike Monahan, remarked, "We had
a number of improvements on a year-over-year basis. We achieved
revenue growth in the second half of 2013 by executing on new
customer acquisition plans we put in place at the beginning of the
year. We successfully improved adjusted EBITDA and adjusted net
income in both the fourth quarter of 2013 and over the full year.
We also grew free cash flow during 2013, enabling us to fund
initiatives to drive future growth." Monahan added, "We are
projecting revenues of $116 million to $121
million for the first quarter of 2014 and $385 million to $405 million for full year 2014.
Earnings per share for the first quarter of 2014 are expected to be
in the range of ($0.07) to ($0.02),
and in the range of $0.51 to $0.61
for full year 2014." The full analyst notes on Nutrisystem Inc. are
available to download free of charge at:
http://www.AnalystsReview.com/03122014/NTRI/report.pdf
--
About Analysts Review
We provide our members with a simple and reliable way to leverage
our economy of scale. Most investors do not have time to track all
publicly traded companies, much less perform an in-depth review and
analysis of the complexities contained in each situation. That's
where Analysts Review comes in. We provide a single unified
platform for investors' to hear about what matters. Situation
alerts, moving events, and upcoming opportunities.
--
=============
EDITOR NOTES:
- This is not company news. We are an independent source and our
views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a
best efforts basis and reviewed by Nidhi Vatsal, a CFA
charterholder. However, we are only human and are prone to make
mistakes. If you notice any errors or omissions, please notify us
below.
- This information is submitted as a net-positive to companies
mentioned, to increase awareness for mentioned companies to our
subscriber base and the investing public.
- If you wish to have your company covered in more detail by our
team, or wish to learn more about our services, please contact us
at pubco [at] AnalystsReview.com.
- For any urgent concerns or inquiries, please contact us
at compliance [at] AnalystsReview.com.
- Are you a public company? Would you like to see similar
coverage on your company? Send us a full investors' package to
research [at] AnalystsReview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort
basis. This document, article or report is prepared and authored by
Analysts Review. An outsourced research services provider
represented by Nidhi Vatsal, CFA, has only reviewed the information
provided by Analysts Review in this article or report according to
the Procedures outlined by Analysts Review. Analysts Review is not
entitled to veto or interfere in the application of such procedures
by the outsourced provider to the articles, documents or reports,
as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to
the accuracy or completeness or fitness for a purpose (investment
or otherwise), of the information provided in this document. This
information is not to be construed as personal financial advice.
Readers are encouraged to consult their personal financial advisor
before making any decisions to buy, sell or hold any securities
mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be
occasioned at the time of printing of this document or any error,
mistake or shortcoming. No liability is accepted by Analysts Review
whatsoever for any direct, indirect or consequential loss arising
from the use of this document. Analysts Review expressly disclaims
any fiduciary responsibility or liability for any consequences,
financial or otherwise arising from any reliance placed on the
information in this document. Analysts Review does not (1)
guarantee the accuracy, timeliness, completeness or correct
sequencing of the information, or (2) warrant any results from use
of the information. The included information is subject to change
without notice.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
AnalystsReview.com
SOURCE Analysts Review